Editorials

Screen all for depression

BMJ 2016; 352 doi: https://doi.org/10.1136/bmj.i1617 (Published 29 March 2016) Cite this as: BMJ 2016;352:i1617
  1. Mark Sinyor, assistant professor1,
  2. Jeremy Rezmovitz, lecturer2 3,
  3. Ari Zaretsky, psychiatrist in chief1 2
  1. 1Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada
  2. 2Department of Psychiatry, University of Toronto, Canada
  3. 3Department of Family and Community Medicine, Sunnybrook Health Sciences Centre
  1. Correspondence to: M Sinyor mark.sinyor{at}sunnybrook.ca

But treat judiciously

Major depressive disorder is a ubiquitous and often devastating condition. It accounts for 2.5% of disability adjusted life years worldwide1 and is the most common mental illness in people who die from suicide.2 In January 2016, the United States Preventive Services Task Force issued updated recommendations calling for universal screening of adults for depression. This was based on its systematic review of five trials with a total of 2924 participants that examined screening in general adult populations.3 The task force concluded that “treatment of adults and older adults with depression identified through screening in primary care settings with antidepressants, psychotherapy, or both decreases clinical morbidity” and that the benefits of screening outweighed its harms.3 This recommendation goes further than those from countries such as the United Kingdom and Canada, where guidelines suggest that clinicians be alert to possible depression, particularly in …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe